Sep 2 2010
Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that it has retained a new FDA consulting company to assist in the preparation and filing of its First Warning System™ 510(k) application.
“Our efforts continue to attempt to re-establish DTC's services regarding the trading of Lifeline's shares.”
Jim Holmes, Lifeline's CEO, said, "The work by the prior FDA consulting firm was partially but not fully completed. The process has caused delays and we have engaged a new firm to assist in the review of our data. There will be a determination as to the adequacy and completeness of our data given the ever-changing FDA requirements. The process is expected to lead to the preparation and filing of our 510(k). We expect to know soon the extent of any additional information this new firm may require in order to complete the 510(k) preparation and submission."
Holmes continued, "Our efforts continue to attempt to re-establish DTC's services regarding the trading of Lifeline's shares."
Source:
: Lifeline Biotechnologies